PedAM
Pediatric Disease Annotations & Medicines
| Disease | nephrogenic systemic fibrosis |
| Phenotype | C1565489|renal insufficiency |
| Sentences | 14 |
| PubMedID- 25945328 | Contrast agent also may cause nephrogenic systemic fibrosis in patients with renal insufficiency. |
| PubMedID- 19128909 | Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the finest study. |
| PubMedID- 23555895 | Compared to pet, pasl-mri is completely noninvasive, less expensive, has no radiation exposure risk, is performed without gadolinium, thus bypassing concerns regarding nephrogenic systemic fibrosis in patients with significant renal insufficiency and can be repeatedly performed on the same subject and on subjects of any age with great ease [15]. |
| PubMedID- 26035645 | Moreover, the need for gadolinium-based contrast agent can occasionally lead to nephrogenic systemic fibrosis in patients with pre-existing renal insufficiency [4–5]. |
| PubMedID- 22571387 | Between 1997 and 2007, more than 500 cases of nephrogenic systemic fibrosis in patients with severe renal insufficiency (glomerular filtration rate less than 30 ml/min/1.73 m(2)) were reported, and no known cases of nephrogenic systemic fibrosis have occurred in patients with a glomerular filtration rate of more than 30 ml/min/1.73 m(2) without acute kidney injury. |
| PubMedID- 23867799 | Gadolinium-based contrast agents are linked to nephrogenic systemic fibrosis in patients with renal insufficiency. |
| PubMedID- 23179483 | However, the advent of nephrogenic systemic fibrosis (nsf) among certain patients with severe renal insufficiency has brought the issue of safety into question. |
| PubMedID- 24778875 | While mr contrast agents have very few side effects [3, 4], they may cause nephrogenic systemic fibrosis (nsf) in patients with renal insufficiency [5]. |
| PubMedID- 20233682 | Macrocyclic gadolinium chelates at low doses should be administered to avoid the risk of nephrogenic systemic fibrosis in patients with renal insufficiency. |
| PubMedID- 22843836 | Some gd-based contrast agents with low thermodynamic stability have been linked to development of nephrogenic systemic fibrosis in patients with severe renal insufficiency. |
| PubMedID- 20725934 | There has recently been renewed interest in noncontrast techniques for peripheral mr angiography following the discovery of an association between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency. |
| PubMedID- 25960650 | Furthermore, mpi operates without contrast agents containing nephrotoxic (iodine based) or serious systemic side effects, ie, nephrogenic systemic fibrosis (gadolinium based) in patients with renal insufficiency.74 the used spions are eliminated via the iron metabolism. |
| PubMedID- 23476099 | Ct contrast agents can cause adverse reaction or renal toxicity [7, 8], while mri contrast agents can increase the risk of nephrogenic systemic fibrosis with renal insufficiency [9–11]. |
| PubMedID- 23390476 | A disadvantage is certainly that, because many patients with irf suffer from renal insufficiency, the risk of gadolinium-associated nephrogenic systemic fibrosis must be carefully considered [18]. |
Page: 1